retatrutide triple agonist glp-1 gip glucagon receptor The TRIUMPH-1 Phase 3 results just dropped on retatrutide. Here is what the numbers actually say. is a agonist. It targets GLP-1, GIP, and receptors. Ozempic targets one. Mounjaro Targeting GLP-1, GIP & GCG

Now, Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes

Multivariate Cox regression analysis was performed using the high-dimensional propensity score (HDPS) to obtain adjusted HR estimates

Unlike oral semaglutide, which must be taken fasting with limited water, orforglipron can be taken at any time of day without food or water restrictions

I was spending $350/month on diabetes medications, blood pressure pills, and cholesterol drugs, says Robert, a Blissful Wellness patient who lost 68 pounds

Standard Titration: For Wegovy, this means starting at 0.25 mg once weekly

Dual agonism with GLP-1 and amylin As WL with GLP-1 RA and amylin analogues results both from distinct and overlapping pathways, a combination of these entero-pancreatic hormones may induce a synergistic WL effect [84]